Boston Scientific Corp (BSX)vsHyperfine Inc (HYPR)
BSX
Boston Scientific Corp
$69.78
+2.39%
HEALTHCARE · Cap: $101.28B
HYPR
Hyperfine Inc
$1.17
+1.74%
HEALTHCARE · Cap: $120.49M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 147906% more annual revenue ($20.07B vs $13.56M). BSX leads profitability with a 14.4% profit margin vs -2.6%. BSX earns a higher WallStSmart Score of 63/100 (C+).
BSX
Buy63
out of 100
Grade: C+
HYPR
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+1.2%
Fair Value
$70.62
Current Price
$69.78
$0.84 discount
Intrinsic value data unavailable for HYPR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
15.9% revenue growth
Generating 1.0B in free cash flow
Revenue surging 128.0% year-over-year
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -79.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bull Case : HYPR
The strongest argument for HYPR centers on Revenue Growth, Price/Book. Revenue growth of 128.0% demonstrates continued momentum.
Bear Case : BSX
The primary concerns for BSX are P/E Ratio.
Bear Case : HYPR
The primary concerns for HYPR are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
BSX profiles as a growth stock while HYPR is a hypergrowth play — different risk/reward profiles.
HYPR carries more volatility with a beta of 1.11 — expect wider price swings.
HYPR is growing revenue faster at 128.0% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (63/100 vs 25/100) and 15.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Hyperfine Inc
HEALTHCARE · MEDICAL DEVICES · USA
Hyperfine Inc. is a pioneer in medical technology, focusing on transforming access to MRI with innovative point-of-care imaging solutions. As the developer of the first FDA-cleared portable MRI system, the company significantly enhances patient care by delivering high-quality imaging directly at the bedside, which streamlines clinical decision-making. By emphasizing cost efficiency and patient convenience, Hyperfine is strategically positioned to capitalize on the escalating demand for advanced diagnostic imaging solutions in a rapidly changing healthcare environment. Its groundbreaking technology is poised to make a substantial impact on healthcare delivery across various medical settings, representing a promising opportunity for institutional investors.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?